Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001144204-17-001361
Filing Date
2017-01-09
Accepted
2017-01-09 16:01:31
Documents
3
Group Members
DAVID E. SHAW

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G v456554_sc13g.htm SC 13G 53722
2 EXHIBIT 1 v456554_ex-1.htm EX-99.1 6166
3 EXHIBIT 2 v456554_ex-2.htm EX-99.2 4684
  Complete submission text file 0001144204-17-001361.txt   66255
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-44055 | Film No.: 17517498
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036
Business Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036 2124780000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

EIN.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G